Literature DB >> 33083371

COVID-19 in a Patient Treated for Granulomatosis with Polyangiitis: Persistent Viral Shedding with No Cytokine Storm.

Pascale Daniel1, Marc Raad2, Rami Waked3, Jacques Choucair3, Moussa Riachy2, Fady Haddad1.   

Abstract

INTRODUCTION: The coronavirus disease COVID-19 is considered a pandemic disease that has developed rapidly all over the world. As of today, it is unclear whether immunosuppression confers an increased risk for pulmonary complications, or conversely, whether it can be a protective factor with respect to a cytokine storm. CASE DESCRIPTION: We report the case of a 55-year-old male patient with granulomatosis with polyangiitis treated with rituximab who was infected with COVID-19 pneumonia. To the best of our knowledge, only 1 case has been reported in the literature with similar characteristics. The patient had a non-classic evolution of clinical symptoms with persistent fever and viral shedding, in addition to a negative serology.
CONCLUSION: This case emphasizes the management and immunity response to COVID-19 pneumonia in such patients. Data are still needed regarding patients who have prolonged B-cell depletion, which may put the patient at a higher risk for reinfection. LEARNING POINTS: Demonstration of the immunity response to COVID-19 pneumonia in an immunosuppressed patient.To highlight the management and evolution of such rare cases during this pandemic. © EFIM 2020.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; granulomatosis with polyangiitis; rituximab

Year:  2020        PMID: 33083371      PMCID: PMC7546569          DOI: 10.12890/2020_001922

Source DB:  PubMed          Journal:  Eur J Case Rep Intern Med        ISSN: 2284-2594


  8 in total

1.  Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic.

Authors:  Lorenzo D'Antiga
Journal:  Liver Transpl       Date:  2020-04-24       Impact factor: 5.799

2.  Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia.

Authors:  Philippe Guilpain; Clément Le Bihan; Vincent Foulongne; Patrice Taourel; Nathalie Pansu; Alexandre Thibault Jacques Maria; Boris Jung; Romaric Larcher; Kada Klouche; Vincent Le Moing
Journal:  Ann Rheum Dis       Date:  2020-04-20       Impact factor: 19.103

3.  Severe SARS-CoV-2 infections: practical considerations and management strategy for intensivists.

Authors:  Lila Bouadma; Francois-Xavier Lescure; Jean-Christophe Lucet; Yazdan Yazdanpanah; Jean-Francois Timsit
Journal:  Intensive Care Med       Date:  2020-02-26       Impact factor: 17.440

4.  The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease.

Authors:  Helena Marco; Rona M Smith; Rachel B Jones; Mary-Jane Guerry; Fausta Catapano; Stella Burns; Afzal N Chaudhry; Kenneth G C Smith; David R W Jayne
Journal:  BMC Musculoskelet Disord       Date:  2014-05-25       Impact factor: 2.362

Review 5.  SARS and MERS: recent insights into emerging coronaviruses.

Authors:  Emmie de Wit; Neeltje van Doremalen; Darryl Falzarano; Vincent J Munster
Journal:  Nat Rev Microbiol       Date:  2016-06-27       Impact factor: 60.633

6.  COVID-19 infection: the perspectives on immune responses.

Authors:  Yufang Shi; Ying Wang; Changshun Shao; Jianan Huang; Jianhe Gan; Xiaoping Huang; Enrico Bucci; Mauro Piacentini; Giuseppe Ippolito; Gerry Melino
Journal:  Cell Death Differ       Date:  2020-03-23       Impact factor: 15.828

7.  Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies.

Authors:  Sara Monti; Silvia Balduzzi; Paolo Delvino; Elisa Bellis; Verdiana Serena Quadrelli; Carlomaurizio Montecucco
Journal:  Ann Rheum Dis       Date:  2020-04-02       Impact factor: 19.103

8.  Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis.

Authors:  Zhaohai Zheng; Fang Peng; Buyun Xu; Jingjing Zhao; Huahua Liu; Jiahao Peng; Qingsong Li; Chongfu Jiang; Yan Zhou; Shuqing Liu; Chunji Ye; Peng Zhang; Yangbo Xing; Hangyuan Guo; Weiliang Tang
Journal:  J Infect       Date:  2020-04-23       Impact factor: 6.072

  8 in total
  7 in total

1.  Effect of Immunosuppressive Diseases and Rituximab Infusions on Allowing COVID-19 Infection to Relapse.

Authors:  Rohan M Prasad; Shaurya Srivastava; Enhua Wang; Jason Z Liu; Rakesh Gami; Ayat Abdelgadir; Akhil Sharma; Sumugdha Rayamajhi; Richa Tikaria
Journal:  Perm J       Date:  2021-10-29

Review 2.  Protracted severe COVID-19 pneumonia following rituximab treatment: caution needed.

Authors:  Dimitrios Daoussis; Lydia Leonidou; Christina Kalogeropoulou; Fotini Paliogianni; Argyrios Tzouvelekis
Journal:  Rheumatol Int       Date:  2021-08-19       Impact factor: 3.580

3. 

Authors:  Clothilde Gros; Alice-Andrée Mariaggi; Jean-François Meritet; Emma André; Margaux Boisson; Alice Combier; Elise Descamps; Camelia Frantz; Sarah Wanono; Jacques Morel; Jérôme Avouac; Flore Rozenberg; Corinne Miceli-Richard; Olivier Fogel
Journal:  Rev Rhum Ed Fr       Date:  2022-05-02

4.  Systematic assessment of the humoral response against SARS-CoV-2 in a French cohort of 283 patients with rheumatic diseases.

Authors:  Clothilde Gros; Alice-Andrée Mariaggi; Jean-François Meritet; Emma André; Margaux Boisson; Alice Combier; Elise Descamps; Camelia Frantz; Sarah Wanono; Jacques Morel; Jérôme Avouac; Flore Rozenberg; Corinne Miceli-Richard; Olivier Fogel
Journal:  Joint Bone Spine       Date:  2021-12-06       Impact factor: 5.263

5.  Progression of COVID-19 in a Patient on Anti-CD20 Antibody Treatment: Case Report and Literature Review.

Authors:  Sebastian Burgener; Philippe Rochat; Günter Dollenmaier; Gabriel Benz; Andreas D Kistler; Rosamaria Fulchini
Journal:  Case Rep Infect Dis       Date:  2022-02-25

6.  COVID-19 Outcomes in Patients Undergoing B Cell Depletion Therapy and Those with Humoral Immunodeficiency States: A Scoping Review.

Authors:  Jessica M Jones; Aiman J Faruqi; James K Sullivan; Cassandra Calabrese; Leonard H Calabrese
Journal:  Pathog Immun       Date:  2021-05-14

Review 7.  COVID-19 pneumonia in a patient with granulomatosis with polyangiitis on rituximab: case-based review.

Authors:  Alicia Rodriguez-Pla; Holenarasipur R Vikram; Vanood Khalid; Lewis J Wesselius
Journal:  Rheumatol Int       Date:  2021-06-06       Impact factor: 2.631

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.